

## References: continued...

### **Dimethyltryptamine:** Possible Endogenous Ligand of the Sigma-1 Receptor?

Adam L. Halberstadt, Ph.D., pages 56-58

- [1] Manske RHF (1931) A synthesis of the methyltryptamines and some derivatives. *Can J Res* 5: 592-600
- [2] Szára S (1956) Dimethyltryptamin: its metabolism in man; the relation to its psychotic effect to the serotonin metabolism. *Experientia* 12: 441-2
- [3] Strassman RJ, Qualls CR (1994) Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects. *Arch Gen Psychiatry* 51: 85-97
- [4] Strassman RJ, Qualls CR, Uhlenhuth EH, Kellner R (1994) Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. *Arch Gen Psychiatry* 51: 98-108
- [5] Smith RL, Canton H, Barrett RJ, Sanders-Bush E (1998) Agonist properties of N,N-dimethyltryptamine at serotonin 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors. *Pharmacol Biochem Behav* 61: 323-330
- [6] Halberstadt AL, Nichols DE (2010) Serotonin and serotonin receptors in hallucinogen action. In: Muller, C., Jacobs, B. (eds) *Handbook of the Behavioral Neurobiology of Serotonin*. Academic, London, pp 621-636.
- [7] Callaway J (1988) A proposed mechanism for the visions of dream sleep. *Med Hypotheses* 26: 119-24
- [8] Strassman R (2001) *DMT: The Spirit Molecule*. Rochester: Park Street Press
- [9] Gillin JC, Kaplan J, Stillman R, Wyatt RJ (1976) The psychedelic model of schizophrenia: the case of N,N-dimethyltryptamine. *Am J Psychiatry* 133: 203-208
- [10] Fontanilla D, Johannessen M, Hajjipour AR, Cozzi NV, Jackson MB, Ruoho AE (2009) The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. *Science* 323: 934-937
- [11] Stefano GB, Goumon Y, Casares F, Cadet P, Fricchione GL, Rialas C, Peter D, Sonetti D, Guarna M, Welters ID, Bianchi E (2000) Endogenous morphine. *Trends Neurosci* 23: 436-442
- [12] Axelrod J (1961) Enzymatic formation of psychotomimetic metabolites from normally occurring compounds. *Science* 134: 343
- [13] Morgan M, Mandell AJ (1969) Indole(ethyl)amine N-methyltransferase in the brain. *Science* 165: 492-493
- [14] Mandell AJ, Morgan M (1971) Indole(ethyl)amine N-methyltransferase in human brain. *Nature* 230: 85-87
- [15] Saavedra JM, Axelrod J (1972) Psychotomimetic N-methylated tryptamines: formation in brain in vivo and in vitro. *Science* 175: 1365-1366
- [16] Saavedra JM, Coyle JT, Axelrod J (1973) The distribution and properties of nonspecific N-methyltransferase in brain. *J Neurochem* 20: 743-752
- [17] Wu PH, Boulton AA (1973) Distribution and metabolism of tryptamine in rat brain. *Can J Biochem* 51: 1104-1112
- [18] Mandell LR, Ahn HS, VandenHeuvel WJA, Walker RW (1972) Indoleamine N-methyltransferase in human lung. *Biochem Pharmacol* 21: 1197-1200
- [19] Boarder MR, Rodnight R (1976) Tryptamine-N-methyltransferase activity in brain tissue: a re-examination. *Brain Res* 114: 359-364
- [20] Rosengarten H, Friedhoff AJ (1976) A review of recent studies of the biosynthesis and excretion of hallucinogens formed by methylation of neurotransmitters or related substances. *Schizophrenia Bull* 2: 90-105
- [21] Rosengarten H, Meller E, Friedhoff AJ (1976) Possible source of error in studies of enzymatic formation of dimethyltryptamine. *J Psychiatric Res* 13: 23-30
- [22] Thompson MA, Weinsilboum RM (1998) Rabbit lung indoleethylamine N-methyltransferase. cDNA and gene cloning and characterization. *J Biol Chem* 273: 34502-34510
- [23] Thompson MA, Moon E, Kim UJ, Xu J, Siciliano MJ, Weinsilboum RM (1999) Human indoleethylamine N-methyltransferase: cDNA cloning and expression, gene cloning, and chromosomal localization. *Genomics* 61: 285-297

**References:** continued...

- [24] Kärkkäinen J, Forsström T, Tornaeus J, Wähälä K, Kiuru P, Honkanen A, Stenman UH, Turpeinen U, Hesso A (2005) Potentially hallucinogenic 5-hydroxytryptamine receptor ligands bufotenine and dimethyltryptamine in blood and tissues. *Scand J Clin Lab Invest* 65: 189-199
- [25] Smythies JR, Morin RD, Brown GB (1979) Identification of dimethyltryptamine and O-methylbufotenin in human cerebrospinal fluid by combined gas chromatography/mass spectrometry. *Biol Psychiatry* 14: 549-56
- [26] Takahashi T, Takahashi K, Ido T, Yanai K, Iwata R, Ishiwata K, Nozoe S (1985) [<sup>11</sup>C]-labeling of indolealkylamine alkaloids and the comparative study of their tissue distributions. *Int J Appl Radiation Isotopes* 36 : 965-969
- [27] Yanai K, Ido T, Ishiwata K, Hatazawa J, Takahashi T, Iwata R, Matsuzawa T (1986) In vivo kinetics and displacement study of a carbon-11-labeled hallucinogen, N,N-(<sup>11</sup>C)dimethyltryptamine. *Eur J Nuclear Med* 12: 141-146.
- [28] Sitaram BR, Lockett L, Talomsin R, Blackman GL, McLeod WR (1987). In vivo metabolism of 5-methoxy-N,N-dimethyltryptamine and N,N-dimethyltryptamine in the rat. *Biochem Pharmacol* 36: 1509-1512
- [29] Wyatt RJ, Mandel LR, Ahn HS, Walker RW, Vanden Heuvel WJ (1973) Gas chromatographic-mass spectrometric isotope dilution determination of N,N-dimethyltryptamine concentrations in normals and psychiatric patients. *Psychopharmacologia* 31: 265-70
- [30] Angrist B, Gershon S, Sathananthan G, Walker RW, Lopez-Ramos B, Mandel LR, Vandenheuvel WJ (1976). Dimethyltryptamine levels in blood of schizophrenic patients and control subjects. *Psychopharmacology* 47: 29-32
- [31] Gintzler AR, Gershon MD, Spector S (1978) A nonpeptide morphine-like compound: immunocytochemical localization in the mouse brain. *Science* 199: 447-448
- [32] Bianchi E, Alessandrini C, Guarna M, Tagliamonte A (1993) Endogenous codeine and morphine are stored in specific brain neurons. *Brain Res* 627: 210-215
- [33] Bianchi E, Guarna M, Tagliamonte A (1994) Immunocytochemical localization of endogenous codeine and morphine. *Adv Neuroimmunol* 4: 83-92
- [34] Neri C, Ghelardini C, Sotak B, Palmiter RD, Guarna M, Stefano G, Bianchi E (2008) Dopamine is necessary to endogenous morphine formation in mammalian brain in vivo. *J Neurochem* 106: 2337-2344
- [35] Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE (1976) The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog. *J Pharmacol Exp Ther* 197: 517-532
- [36] Jasinski DR, Martin WR, Sapira JD (1968) Antagonism of the subjective, behavioral, pupillary, and respiratory depressant effects of cyclazocine by naloxone. *Clin Pharmacol Ther* 9: 215-222
- [37] Pfeiffer A, Brantl V, Herz A, Emrich HM (1986) Psychotomimesis mediated by kappa opiate receptors. *Science* 233: 774-776
- [38] Musacchio JM (1990) The psychotomimetic effects of opiates and the sigma receptor. *Neuropsychopharmacology* 3: 191-200
- [39] Sadzot B, Baraban JM, Glennon RA, Lyon RA, Leonhardt S, Jan CR, Titeler M (1989) Hallucinogenic drug interactions at human brains 5-HT<sub>2</sub> receptor: implications for treating LSD-induced hallucinogenesis. *Psychopharmacology* 98: 495-499
- [40] Hayashi T, Su TP (2007) Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca<sup>2+</sup> signaling and cell survival. *Cell* 131: 596-610